$27.5M Credit Facility Bolsters Verrica’s YCANTH Expansion Plans
Event summary
- Verrica Pharmaceuticals secured a $27.5M credit facility from an entity controlled by Chairman Paul B. Manning, its largest shareholder.
- Facility supports YCANTH® commercialization and global Phase 3 trials for common warts, with no scheduled payments until December 2030.
- $12.5M immediately available, with additional $15M contingent on revenue and operational milestones.
- Interest rate set at SOFR + 8%, with a floor of 4.5%, payable in kind until maturity.
- Company projects facility could extend cash runway into 2028 under current operating plan.
The big picture
Verrica’s credit facility underscores its strategic pivot toward dermato-oncology, with YCANTH positioned as a cornerstone product. The non-dilutive financing aligns with broader biotech trends of leveraging shareholder-backed capital to extend runway without equity dilution. Success hinges on executing Phase 3 trials and scaling commercial reach in an underserved dermatology segment.
What we're watching
- Commercial Execution
- How Verrica will leverage the non-dilutive capital to accelerate YCANTH adoption in molluscum and expand into common warts.
- Clinical Milestones
- Whether the global Phase 3 program for common warts meets mid-2027 data readout targets, potentially unlocking a larger market opportunity.
- Financial Flexibility
- The pace at which Verrica achieves revenue and operational milestones to access the full $27.5M facility.